News
The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...
Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...
Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...
Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to what could be a ...
Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...
PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...
With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit ...
BRIDGEWATER – Shares of Insmed, a pharmaceutical firm at the intersection of Route 202-206 and Allen Road, jumped 8% on the NASDAQ after the federal Food and Drug Administration approved the company's ...
Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...
Insmed has won U.S. Food and Drug Administration approval of Brinsupri as the first and only treatment for the chronic lung disease non-cystic fibrosis bronchiectasis. Insmed on Tuesday said the FDA ...
The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated’s (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results